International Journal of Medicine and Pharmaceutical Research
E-ISSN: 2321-2624 | https://doi.org/10.30904/j.ijmpr.2026.5005

An Evaluation of Regulatory Pathways for Vaccine Development and Approval in Developed Versus Emerging Markets

Sriramojula Archithasri*, P. Laxmi, K. Chaitanya Prasad, K Shravan Kumar

Samskruti College of Pharmacy, Kondapur, Ghatkesar, Medchal, Hyderabad-501301, Telangana, India
***Corresponding E-Mail:** principal.y7@gmail.com*

Received: 29-04-2026 | Revised: 30-05-2026 | Accepted: 23-06-2026 | Published: 10-07-2026

ABSTRACT:
The aim of this thesis is to evaluate, compare, and synthesize vaccine regulatory pathways in selected developed versus emerging markets, with the overarching goal of identifying practical levers to shorten time-to-access without compromising the core pillars of quality, safety, and efficacy. This evaluation seeks to enhance both regulatory efficiency and global equity in vaccine availability. This work conducted a comprehensive evaluation of vaccine regulatory pathways across developed and emerging markets, identifying both convergences and divergences in practices, processes, and capacities. Several key themes emerged: Convergence is growing but uneven: Regulatory systems worldwide increasingly share common features such as conditional approvals, rolling reviews, and reliance mechanisms. However, these mechanisms are more mature and consistently applied in developed markets, while adoption in LMICs remains uneven and resource-dependent. Reliance and rolling reviews as pivotal accelerators: Evidence from the COVID-19 pandemic demonstrates that reliance on WHO PQ/EUL and other global authorities, combined with rolling review models, significantly shortens time-to-market without compromising standards. CMC and pharmacovigilance capacity as persistent bottlenecks: Emerging markets often face resource limitations in conducting rigorous CMC reviews, GMP inspections, lot release testing, and maintaining robust PV systems. These gaps contribute to delays and uneven safety oversight. Policy options and sponsor strategies: Specific, feasible actions can be taken to compress regulatory timelines while preserving scientific rigor. These include embedding reliance frameworks in law, investing in regulatory infrastructure, pre-arranging lot release testing capacity, and leveraging digital traceability systems.
Keywords: Quality, safety, efficacy, WHO PQ/EUL, CMC

Introduction

Vaccination is recognized as one of the most cost-effective public health interventions ever developed, saving millions of lives annually and preventing the spread of infectious diseases across the globe. From the eradication of smallpox to the near elimination of polio and the substantial reductions in measles, diphtheria, tetanus, and pertussis-related morbidity, vaccines have reshaped global health. More recently, the rapid development and deployment of COVID-19 vaccines demonstrated the unparalleled importance of efficient regulatory frameworks to ensure both timely access and uncompromised safety.

However, vaccine development differs significantly from that of small-molecule drugs or even other biologics. Vaccines involve complex manufacturing processes, stringent quality control requirements, and unique clinical endpoints, such as immunogenicity and correlates of protection. As such, the regulatory landscape governing vaccines is multifaceted, and varies significantly between developed markets—such as the US, EU, UK, Japan, Canada, and Australia—and emerging markets, including India, China, Brazil, South Africa, Indonesia, and other LMICs. These differences influence not only approval timelines but also global access, equitable distribution, and public trust in vaccines.

The development-to-market continuum for vaccines requires the careful orchestration of scientific evidence, manufacturing readiness, regulatory review, and post-marketing surveillance. While developed markets generally benefit from robust infrastructures and sophisticated regulatory processes, emerging markets must often balance resource limitations with urgent public health needs. Understanding these differences is essential to inform policy reforms and optimize regulatory strategies for global vaccine equity.

Historical Context

The historical evolution of vaccine regulation reflects responses to crises, scientific breakthroughs, and shifts in global public health priorities:

- Early 20th century: Vaccine safety incidents (e.g., the 1901 diphtheria antitoxin contamination in the US) spurred early legislation, such as the Biologics Control Act of 1902, laying the foundation for biologics oversight.
- Post-World War II: WHO and other international organizations began promoting global immunization programs, highlighting the need for international regulatory coordination.
- Late 20th century: The HIV/AIDS pandemic reinforced the need for accelerated regulatory mechanisms and international harmonization through bodies like ICH.

- 21st century: Emerging infectious diseases (SARS, H1N1, Ebola, Zika, and COVID-19) emphasized the need for flexible but reliable emergency pathways, reliance mechanisms, and enhanced pharmacovigilance.

This historical trajectory illustrates that regulatory reforms are often reactive, driven by crises, and highlight the need for more proactive harmonization and convergence to prepare for future pandemics.

Table 1: Historical Evolution of Vaccine Regulation

Period	Key Events	Regulatory Impact
Early 20th century	1901 diphtheria antitoxin contamination; Biologics Control Act (1902)	Established first biologics oversight law in the US
Post-World War II	Launch of WHO immunization programs	Highlighted global need for coordination in vaccine regulation
Late 20th century	HIV/AIDS pandemic	Led to accelerated pathways, strengthened PV, and ICH creation for harmonization
21st century	SARS, H1N1, Ebola, Zika, COVID-19	Catalyzed rolling reviews, reliance mechanisms, emergency authorizations, and global PV reforms

Problem Statement

Despite significant global efforts to harmonize and strengthen regulatory frameworks through initiatives such as ICH, ICMRA, and WHO Prequalification, disparities persist:

- Complexity and duplication: Multinational vaccine developers often face duplicative dossier submissions, redundant trials, and prolonged timelines in emerging markets.
- Capacity gaps: Many LMIC regulatory authorities lack sufficient expertise, infrastructure, and resources to conduct in-depth CMC reviews, GMP inspections, or robust pharmacovigilance.
- Delayed access: Populations in emerging markets often experience vaccine availability months or years later than those in developed markets.
- Trust and misinformation: Regulatory delays and opaque communication further contribute to vaccine hesitancy and misinformation.

A structured comparative evaluation of regulatory pathways across developed and emerging markets is therefore essential to identify convergence opportunities and ensure equitable global vaccine access.

1.4 Scope and Comparative Framework

This thesis systematically evaluates regulatory frameworks for vaccine approval across developed and emerging markets. The scope includes:

- Institutional and legal frameworks: Roles of national regulatory authorities (e.g., USFDA, EMA, CDSCO, NMPA, ANVISA, SAHPRA, BPOM).
- Development stages: Early advice/pre-IND processes, Phase I–III clinical trials, pediatric investigation plans, and Phase IV commitments.
- Quality/CMC considerations: Platform technologies (mRNA, viral vectors, recombinant subunits), analytical method validation, comparability, cold-chain and stability, lifecycle management.
- Regulatory pathways: Standard approval, conditional/accelerated approval, rolling review, emergency use authorizations, PRIME (EU), Sakigake (Japan), Provisional Approval (Australia).
- Reliance and convergence frameworks: WHO PQ/EUL, regional initiatives (AVAREF, PAHO, ASEAN).
- Post-market surveillance: Pharmacovigilance frameworks, AEFI monitoring, RMPs, and batch traceability systems.
- Ethics and public trust: Transparent communication, addressing misinformation, equitable trial placement.

This framework allows structured comparison between regulatory environments, highlighting convergence areas and persistent gaps.

Methodology

Study Design

This study adopts a comparative regulatory policy analysis design, employing a mixed-methods approach to comprehensively evaluate vaccine regulatory pathways in developed and emerging markets. The methodology combines:

- Structured document review of regulatory frameworks, statutes, and official guidance documents.
- Targeted secondary data abstraction from public dashboards, timelines, case studies, and inspection reports.
- Qualitative synthesis of narrative and policy insights, supplemented by tabular comparison and descriptive statistics where feasible.

This approach enables both breadth (systematic cross-jurisdictional comparison) and depth (contextual analysis of pathways, timelines, and outcomes).

Jurisdictional Selection

Jurisdictions were selected based on their relevance to global vaccine regulation and representativeness of developed versus emerging market contexts.

- Developed markets: United States (USFDA/CBER), European Union (EMA/CHMP), United Kingdom (MHRA), Japan (PMDA), Canada (Health Canada), and Australia (TGA).
- Emerging markets: India (CDSCO), China (NMPA), Brazil (ANVISA), South Africa (SAHPRA), and Indonesia (BPOM).
- **Cross-cutting global mechanism:**
  WHO PQ/EUL, as it is essential for LMIC vaccine access through procurement agencies such as UNICEF and Gavi.

This selection balances mature regulatory authorities, evolving agencies, and global harmonization mechanisms.



Figure.1: Jurisdictional Selection (developed, emerging, and global WHO PQ/EUL).

Data Sources

Data collection draws from multiple sources to ensure comprehensiveness:

- Primary regulatory documents: National statutes, regulations, official guidance documents, and agency annual reports.
- Global and regional guidance: WHO PQ/EUL procedures, ICH and ICMRA communiqués, PAHO, AVAREF, and ASEAN publications.
- Secondary literature: Peer-reviewed academic articles and grey literature from recognized institutions (e.g., World Bank, OECD, CEPI, Gavi).
- Dashboards and datasets: Publicly available timelines and regulatory performance metrics.
- Case studies and inspection reports: Publicly accessible sponsor submissions, advisory committee summaries, and inspection outcomes.

Variables and Operational Definitions

Key variables were operationalized as follows:

- Pathway types: Standard/regular approval, conditional approval, accelerated assessment, rolling review, EUA/EUL.
- Timelines: Median or mean days from submission/validation to approval; duration of rolling review where available.
- CMC rigor: Indicators include number of review cycles, issuance of deficiency letters, requirement for on-site vs remote inspections, and lot release protocols.
- Pharmacovigilance (PV) maturity: Mandatory Risk Management Plans (RMPs), presence of active surveillance systems, and reporting frequency (PSUR/PBRER cadence).
- Reliance use: Explicit legal basis for reliance or recognition, documented instances of usage, and frequency.

Data Extraction and Quality Appraisal

To ensure methodological rigor and transparency, the study employed a structured approach to data extraction and quality appraisal, combining standardized tools, dual review, and systematic evaluation of source credibility.

Data Extraction

- A standardized extraction form was developed and applied across all jurisdictions under study. This ensured uniformity and comparability of data points, regardless of regulatory context. Key variables extracted included:
- Regulatory Features: Structural and procedural requirements within the eCTD and related submission frameworks.
- Timelines: Statutory review deadlines, performance goals, and observed deviations.
- Pharmacovigilance (PV) Obligations: Pre- and post-approval safety monitoring requirements specific to each authority.
- Reliance Mechanisms: Pathways such as mutual recognition, abridged reviews, or reliance on reference agencies.
- Extraction was conducted systematically, with each regulatory guideline, secondary report, or case study reviewed in full to identify relevant entries for the matrix. This structured process minimized the risk of omission and allowed for efficient cross-jurisdictional comparison.

Dual Review

- Where feasible, data extraction was performed by two independent reviewers working in parallel. Each reviewer coded and recorded findings using the standardized form.
- Reconciliation: Any discrepancies in extracted data (e.g., interpretation of timelines or classification of obligations) were resolved through consensus discussions, with escalation to a third reviewer in rare cases of persistent disagreement.
- Benefit: This dual review process strengthened the reliability and reproducibility of findings by reducing individual bias.

Quality Appraisal

- All included sources were subjected to a structured quality appraisal framework, with three core criteria:
- Credibility: Official regulatory documents (e.g., USFDA guidance, EMA notices, CDSCO circulars) were prioritized as primary sources. Secondary sources (peer-reviewed articles, industry reports) were included where they offered contextual insights but were critically appraised for potential interpretive bias.
- Recency: Preference was given to most recent versions of regulatory texts and reports. Outdated documents were included only when historically relevant and were flagged for cautious interpretation.
- Internal Consistency: Sources were checked for coherence and alignment with related guidelines. Documents showing inconsistencies with current official standards were documented but treated with caution.
- By systematically applying these criteria, the study ensured that the evidence base remained both credible and contextually relevant, while explicitly acknowledging the limitations of older or conflicting documents.

Comparative Analysis Plan

- Comparative tables: Systematic side-by-side comparison of jurisdictions across pathway features, CMC standards, reliance mechanisms, and PV obligations (see Tables 4.x).
- Narrative synthesis: Interpretation of patterns, highlighting areas of alignment and divergence.
- Descriptive statistics: Where sufficient data are available, timeline comparisons (median days to approval, range) will be analyzed. Non-parametric statistical methods may be used to address heterogeneity and small sample sizes.

Limitations

Several methodological limitations were anticipated:

- Data constraints: Reliance on publicly available information may omit confidential or unpublished practices. Temporal heterogeneity: Regulatory reforms evolve over time, and datasets may span different regulatory eras.
- Granularity gaps: Limited availability of disaggregated CMC metrics (e.g., number of review cycles or inspection delays).
- COVID-19 artifacts: Pandemic-era timelines may not reflect routine regulatory performance and thus require contextual interpretation.

Results and Discussion

Overview of Pathways by Jurisdiction

This section provides an integrated overview of the regulatory pathways across both developed and emerging markets. Each jurisdiction exhibits unique legal bases, institutional structures, and procedural mechanisms, but there are commonalities in reliance on scientific evidence, safety monitoring, and expedited approvals during emergencies.

- Developed markets: Feature mature regulatory systems with multiple accelerated and conditional pathways, extensive scientific advice mechanisms, structured advisory committees, and robust lot release and pharmacovigilance obligations.
- Emerging markets: Increasingly sophisticated but often resource-constrained, these systems rely heavily on WHO PQ/EUL and regional reliance initiatives. They show variability in lot release rigor and pharmacovigilance maturity, with some agencies (e.g., NMPA, CDSCO) rapidly strengthening capacity.

Developed Markets – Detailed Findings

USFDA (CBER)

- Process: IND process followed by BLA submission, reviewed by CBER. Advisory committees: VRBPAC plays a central role in major vaccine approvals.
- Expedited programs: Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval. EUA widely used during COVID-19. Post-marketing commitments: Include RMPs, long-term safety, and effectiveness studies.
- Pharmacovigilance: VAERS, Vaccine Safety Datalink (VSD), and PRISM networks enable active and passive monitoring.

EMA

- Centralized procedure: All vaccines reviewed through CHMP.
- Expedited mechanisms: Conditional Marketing Authorization, Exceptional Circumstances, Accelerated Assessment, and Rolling Reviews (COVID-19).
- PRIME designation: Provides enhanced scientific advice.
- Pharmacovigilance: Eudra Vigilance, QPPV, and mandatory RMPs underpin strong safety systems.

MHRA

- Post-Brexit: Independent authorizations, with selective reliance on EMA/EU Commission decisions.
- COVID-19 response: Rapid conditional approvals and rolling reviews.
- Lot release: Conducted by the National Institute for Biological Standards and Control (NIBSC).
- Pharmacovigilance: Yellow Card system ensures robust post-marketing monitoring.

PMDA (Japan)

- Sakigake designation: Prioritizes innovative products.
- Conditional Early Approval: Applied to serious diseases.
- Lot release: Overseen by National Control Laboratories.
- PV system: Includes mandatory reporting and periodic re-examination.

Health Canada & TGA

- Interim orders (Canada) and provisional approvals (Australia) facilitated COVID-19 vaccine rollouts.
- Rolling reviews widely adopted.
- Pharmacovigilance: Canada Vigilance and Aus Vax Safety are central systems, complemented by global reliance initiatives.

Emerging Markets detailed findings:

India (CDSCO/DCGI)

India's regulatory landscape is governed by the New Drugs and Clinical Trials Rules (2019), which provide the framework for both standard and accelerated approvals. During the COVID-19 pandemic, restricted emergency approvals were granted for vaccines, often contingent on bridging studies using Indian populations to confirm safety and immunogenicity. The Subject Expert Committee (SEC) played a central advisory role, providing technical recommendations for decision-making. Lot release responsibilities are shared between the Central Drugs Laboratory (CDL) and the National Institute of Biologicals (NIB). Post-marketing safety monitoring is conducted through the Pharmacovigilance Programme of India (PvPI) and Adverse Event Following Immunization (AEFI) systems. However, both face capacity limitations, especially in terms of digital reporting infrastructure and rural coverage, which constrain their effectiveness in active safety surveillance.

China (NMPA)

China's National Medical Products Administration (NMPA) has emerged as one of the most progressive regulators in terms of accelerated pathways. The system supports Conditional Approvals, Priority Reviews, and real-time review frameworks, which were extensively utilized during the COVID-19 emergency. The NMPA maintains strict on-site inspections,

which remain a cornerstone of its oversight system and a barrier for sponsors seeking rapid access without robust GMP compliance. Pharmacovigilance systems are undergoing rapid modernization, with the rollout of mandatory adverse event reporting and digital safety-tracking platforms. This modernization aligns China more closely with global standards, though implementation challenges persist at provincial levels.

Brazil (ANVISA)

Brazil's regulatory authority, ANVISA, relies on RDC regulations that provide for conditional approvals and reliance mechanisms. Lot release functions are managed by national laboratories, often in collaboration with the World Health Organization (WHO), ensuring quality assurance for vaccines and biologicals. Reliance mechanisms are particularly strong in Brazil, with integration into PAHO's regional frameworks and WHO prequalification (PQ) programs, which facilitate market access while reducing duplicative reviews. This reliance approach has supported Brazil in balancing timely access with regulatory robustness, especially in pandemic contexts.

South Africa (SAHPRA)

South Africa's SAHPRA has historically faced severe application backlogs, but targeted reduction strategies—including simplified review processes and external reliance—have improved throughput. Reliance is a dominant feature, with heavy dependence on AVAREF (African Vaccine Regulatory Forum), WHO PQ, and foreign regulatory authority assessments. Pharmacovigilance is supported through AEFI committees and WHO-backed sentinel surveillance systems, although coverage and responsiveness are limited by resource constraints. While reliance mechanisms enable efficiency, they also underscore gaps in SAHPRA's independent capacity for complex assessments.

Indonesia (BPOM)

Indonesia's BPOM manages both standard national approvals and conditional pathways, including Emergency Use Authorizations (EUAs). The country actively participates in ASEAN Mutual Recognition Arrangements (MRAs), benefiting from collaborative review frameworks that streamline access to regional markets. Pharmacovigilance systems are in early stages of maturity, with progressive integration of WHO standards. However, the system remains developing, with uneven adoption across provinces and limited real-time data infrastructure.

Cross-Cutting Findings

The analysis of emerging market regulators highlights both progress and persistent challenges:

1. Reliance on WHO and Regional Platforms: Reliance on WHO PQ/EUL, PAHO frameworks, AVAREF, and ASEAN MRAs is central to enabling timely market access, particularly for vaccines in low- and middle-income countries (LMICs). While this ensures efficiency, it also reflects capacity gaps in conducting independent full-scale reviews.
2. Manufacturing Expansion: Technology transfer partnerships and fill-finish hubs have been critical in scaling up local manufacturing capacity, especially in India, Brazil, and Indonesia. These hubs improve vaccine availability and strengthen self-reliance, though quality oversight remains variable.
3. Pharmacovigilance and Lot Release Gaps: Despite rapid progress, pharmacovigilance systems remain underdeveloped in several contexts, with gaps in real-time tracking, digital infrastructure, and active surveillance. Similarly, lot release systems are often reliant on external collaboration with WHO or national laboratories, limiting autonomous regulatory assurance.



Figure 2: Timeline Distribution

Discussion

The findings highlight the dual trajectory of emerging regulators:

- On one hand, convergence with global practices is visible in the adoption of conditional approvals, reliance mechanisms, and digital PV modernization.
- On the other, structural weaknesses—including uneven PV capacity, dependence on WHO and foreign reviews, and resource constraints—continue to limit regulatory sovereignty.

For global pharmaceutical stakeholders, these dynamics imply that while emerging markets offer accelerated access opportunities, sponsors must prepare for regulatory heterogeneity, lot release delays, and post-market obligations that vary considerably across regions.

Table 2: USFDA (CBER) – Jurisdiction Profile

Dimension	Key Features
Legal Basis	FD&C Act; Public Health Service (PHS) Act
Pathways	Standard BLA; Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval, EUA
Scientific Advice	Pre-IND meetings, Type B/C consultations
Lot Release	Conducted by CBER Official Control Labs
Pharmacovigilance	VAERS, Vaccine Safety Datalink (VSD), PRISM
Reliance	Limited; participates in ICMRA initiatives

Table 3: EMA – Jurisdiction Profile

Dimension	Key Features
Legal Basis	EU Directives & Regulations; centralized procedure mandatory for vaccines
Pathways	Standard MA, Conditional MA, Exceptional Circumstances, Accelerated Assessment, Rolling Review, PRIME
Scientific Advice	CHMP Scientific Advice, SAWP, PRIME early support
Lot Release	OMCL system (e.g., PEI, NIBSC)
Pharmacovigilance	EudraVigilance, QPPV, mandatory RMPs
Reliance	ICMRA, MRAs, collaboration with WHO

Table 4: MHRA – Jurisdiction Profile

Dimension	Key Features
Legal Basis	UK Medicines Act; independent post-Brexit regulatory authority
Pathways	Standard approval; Conditional Authorizations; Rolling Reviews; EUA
Scientific Advice	National Scientific Advice; early engagement programs
Lot Release	NIBSC
Pharmacovigilance	Yellow Card system; active post-marketing requirements
Reliance	Selective post-Brexit recognition and reliance on trusted authorities

Table 5: PMDA (Japan) – Jurisdiction Profile

Dimension	Key Features
Legal Basis	Pharmaceutical and Medical Devices Act (PMD Act)
Pathways	Standard NDA/BLA; Sakigake designation; Conditional Early Approval
Scientific Advice	Formal PMDA scientific consultations
Lot Release	National Control Laboratories
Pharmacovigilance	PMDA-mandated reporting; periodic re-examinations
Reliance	Bilateral reliance pilots

Table 6: Health Canada – Jurisdiction Profile

Dimension	Key Features
Legal Basis	Food and Drugs Act, Food and Drug Regulations
Pathways	Standard NDS; Interim Orders; Conditional Pathways; Rolling Review
Scientific Advice	Pre-submission advice meetings
Lot Release	National Control Laboratories
Pharmacovigilance	Canada Vigilance Program; mandatory RMPs
Reliance	MRAs; ICMRA

Table 7: TGA (Australia) – Jurisdiction Profile

Dimension	Key Features
Legal Basis	Therapeutic Goods Act; Australian regulatory guidelines for vaccines
Pathways	Standard Registration; Provisional Approval; Rolling Review; EUA (COVID-19)
Scientific Advice	Pre-submission advice
Lot Release	TGA labs; OCABR reliance
Pharmacovigilance	AusVaxSafety; active safety monitoring
Reliance	MRAs; ICMRA

Conclusion

The comparative analysis reveals that global regulatory pathways for vaccines are converging in principle but diverging in practice. Developed markets maintain high-capacity, resource-rich systems that can accommodate complex CMC reviews and extensive pharmacovigilance commitments. In contrast, emerging markets rely heavily on global and regional mechanisms to ensure timely access, with varying success. The COVID-19 pandemic served as a critical stress test, demonstrating the power of rolling reviews, reliance networks, and emergency authorizations to accelerate access. These lessons highlight opportunities to embed such innovations into permanent frameworks. However, without substantial investment in capacity building particularly in CMC rigor, GMP inspection, and pharmacovigilance systems—the disparities between developed and emerging markets will persist.

Implications for Policy and Practice

- Regulators should embed reliance and rolling review frameworks in law, publish transparent performance metrics, and invest in inspection and PV capacity.
- Sponsors should design global evidence packages that anticipate reliance use, engage early with regulators, and adopt modular CMC strategies.
- Global health actors must continue to finance and support NRA maturity, expand WHO PQ/reliance networks, and invest in PV and cold-chain infrastructure.

Closing Perspective

Ultimately, vaccine regulation is a balancing act between speed and safety, innovation and equity. This thesis underscores that regulatory convergence is achievable, reliance is effective, and bottlenecks can be addressed with targeted reforms. By implementing the proposed policy and sponsor strategies, stakeholders can compress timelines, enhance global preparedness, and ensure that vaccines reach populations faster—without sacrificing the core principles of quality, safety, and efficacy.

Funding

This study received no specific funding from public, commercial, or not for profit funding agencies.

AI Tool Declaration

The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

Conflict of Interests

The authors declare no conflict of interest

Data Availability

Data will be available on request

References

[1] US Food and Drug Administration (FDA). Guidance for industry: Development and licensure of vaccines to prevent COVID-19. Silver Spring, MD: FDA; 2020.

[2] European Medicines Agency (EMA). Guideline on clinical evaluation of new vaccines. EMA/ CHMP/ VWP/164653/ 05; 2018.

[3] Medicines and Healthcare products Regulatory Agency (MHRA). Guidance on regulation of COVID-19 vaccines. London: MHRA; 2021.

[4] Pharmaceuticals and Medical Devices Agency (PMDA). Review report: Vaccine products. Tokyo: PMDA; 2021.

[5] Health Canada. Guidance for market authorization requirements for COVID-19 vaccines. Ottawa: Health Canada; 2020.

[6] Therapeutic Goods Administration (TGA). Australian regulatory guidelines for vaccines. Canberra: TGA; 2019.

[7] Central Drugs Standard Control Organization (CDSCO). New Drugs and Clinical Trials Rules. New Delhi: CDSCO; 2019.
[8] National Medical Products Administration (NMPA). Technical guidelines for vaccine registration. Beijing: NMPA; 2020.
[9] Agência Nacional de Vigilância Sanitária (ANVISA). RDC No. 55/2010: Registration of vaccines. Brasília: ANVISA; 2010.
[10] South African Health Products Regulatory Authority (SAHPRA). Guideline on emergency use authorization of vaccines. Pretoria: SAHPRA; 2021.
[11] Badan Pengawas Obat dan Makanan (BPOM). Regulation on vaccine approvals in Indonesia. Jakarta: BPOM; 2020.
[12] World Health Organization (WHO). Emergency Use Listing procedure. Geneva: WHO; 2020.
[13] World Health Organization (WHO). Prequalification of vaccines for procurement. Geneva: WHO; 2019.
[14] International Council for Harmonisation (ICH). Guideline for Good Clinical Practice E6(R2). Geneva: ICH; 2016.
[15] International Council for Harmonisation (ICH). Quality guidelines for biological products. Geneva: ICH; 2020.
[16] International Coalition of Medicines Regulatory Authorities (ICMRA). Joint statement on reliance. 2021.
[17] Pan American Health Organization (PAHO). Regulatory reliance principles for vaccine approvals. Washington, DC: PAHO; 2019.
[18] African Vaccine Regulatory Forum (AVAREF). Operational guidance. Geneva: WHO; 2020.
[19] Association of Southeast Asian Nations (ASEAN). Harmonized requirements for vaccine registration. Jakarta: ASEAN; 2018.
[20] World Bank. Vaccine regulation and access in LMICs: Policy note. Washington, DC: World Bank; 2021.
[21] Gavi, the Vaccine Alliance. The role of regulatory alignment in COVAX. Geneva: Gavi; 2021.
[22] Coalition for Epidemic Preparedness Innovations (CEPI). Accelerating vaccine development through regulatory science. Oslo: CEPI; 2020.
[23] Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Vaccines. 7th ed. Philadelphia: Elsevier; 2018.
[24] Røttingen JA, Gouglas D, Feinberg M, Plotkin S, Raghavan KV, Witty A. New vaccines against epidemic infectious diseases. N Engl J Med. 2017; 376(7): 610-613.
[25] Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R. COVID-19 vaccine trials and approval: Principles and practice. Lancet. 2021; 397(10269): 1011-1013.
[26] Lurie N, Saville M, Hatchett R, Halton J. Developing COVID-19 vaccines at pandemic speed. N Engl J Med. 2020; 382(21): 1969-1973.
[27] Kieny MP, Salama P. WHO R&D blueprint: Accelerating vaccine development. Vaccine. 2017; 35(9):1202-1206.
[28] Black S, Bloom DE, Kaslow DC. The importance of regulatory harmonization in vaccine development. Vaccine. 2020; 38(28): 4395-4399.
[29] Jaffe S. Regulatory frameworks for vaccines: A global perspective. Nat Rev Drug Discov. 2019; 18(1):7-8.
[30] Gupta Y, Dube A, Prasad D. Regulatory challenges for vaccine approvals in India. Indian J Pharmacol. 2020; 52(5): 365-371.
[31] Wang Y, Li X, Cao B. Regulatory landscape for vaccines in China. Vaccine. 2021; 39(3):411-417.
[32] Cavalcanti R, Silva C, Souza A. Vaccine regulation in Brazil: ANVISA and regional reliance. Rev Saude Publica. 2019; 53: 22.
[33] Gray A, Reddy C. Strengthening SAHPRA: Regulatory reform in South Africa. S Afr Med J. 2020; 110(9): 873-877.
[34] Nugroho A, Setiawan A. Challenges in vaccine approval processes in Indonesia. Indones J Health Policy. 2021; 10(2): 123-129.
[35] Hintzen P, Hauben M, Bate A. Global pharmacovigilance for vaccines. Drug Saf. 2019; 42(10): 1111-1122.
[36] Bonhoeffer J, Kohl K, Chen RT, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: Improving vaccine safety assessment. Vaccine. 2002; 21(3-4): 298-302.
[37] Rath B, Bentsi-Enchill A, Cheuvart B. Vaccine safety surveillance in LMICs. Vaccine. 2021; 39(28): 3742-3749.
[38] Vannice KS, Prasad S, Fenton Hall L. Ethical considerations in vaccine trials. Vaccine. 2019; 37(25): 3223-3229.
[39] Kim JH, Marks F, Clemens JD. Looking beyond COVID-19: Strengthening vaccine regulation for future pandemics. Lancet. 2021; 398(10299): 1407-1409.
[40] Pagliusi S, Jarrett S, Hayman B, Kreysa U. Vaccine manufacturing and regulatory challenges. Vaccine. 2020; 38(32): 5122-5130.
[41] Thacker N, Ghosh S, Dhar A. Cold chain and vaccine stability challenges in LMICs. Vaccine. 2020; 38(30):4751-4757.
[42] Prat A, Sinha S, Rajeshwari K. Regulatory convergence and reliance for equitable vaccine access. Health Policy. 2021; 125(9):1205-1214.